Papers And Originals

Use of Amantadine in Parkinson's Disease. Results of a Double-blind Trial

Br Med J 1970; 4 doi: https://doi.org/10.1136/bmj.4.5726.24 (Published 03 October 1970) Cite this as: Br Med J 1970;4:24

This article has a correction. Please see:

  1. Vera Dallos,
  2. Kenneth Heathfield,
  3. Patricia Stone,
  4. F. A. D. Allen

    Abstract

    In a four-week double-blind trial of 62 patients with Parkinsonism 29 were treated withamantadine and 33 with a placebo. Modest but statistically significant improvement was observed in the first group, optimum benefit occurring after the first two weeks. Patients' reactions to the drug were favourable in 79%, and side effects were insignificant. Though amantadine appears to be a useful additive drug in the treatment of Parkinsonism, its value as a single treatment is as yet undetermined.